SML1455
DAA-I acetate salt
≥98% (HPLC)
别名:
5-L-Isoleucine-2-10-Angiotensin I acetate salt, Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu acetate, RVYIHPFHL acetate, [Des-Asp1-Ile5]angiotensin I, des-Asp-angiotensin I acetate, des-aspartate-angiotensin-I acetate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C58H84N16O11 · xC2H4O2
化学文摘社编号:
分子量:
1181.39 (free base basis)
NACRES:
NA.77
UNSPSC Code:
12352200
Biochem/physiol Actions
DAA-I (des-aspartate-angiotensin-I) is an agonist on the angiotensin AT1 receptor and releases prostaglandins which mediate its actions. DAA-I administer at doses lesser than Km of metabolizing enzymes antagonize the deleterious actions of angiotensin II. DAA-I appear function in vivo as a physiological antagonist to angiotensin II.
DAA-I (des-aspartate-angiotensin-I) is an agonist on the angiotensin AT1 receptor.
Des-aspartate-angiotensin I (DAA-I) is a nine-amino acid angiotensin peptide and a metabolite of angiotensin DAA-I mediates attenuation of early inflammatory processes and intercellular adhesion molecule-1 (ICAM-1) formation in animal models.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Meng-Kwoon Sim et al.
Endocrinology, 148(12), 5925-5932 (2007-09-08)
The present study investigated the hypoglycemic action of des-aspartate-angiotensin I (DAA-I), a metabolite of angiotensin I, in two animal models of type 2 diabetes. The rationale was based on our earlier studies demonstrating that DAA-I acts on the angiotensin AT(1)
Eugene Teck-Leong Ng et al.
Journal of applied toxicology : JAT, 31(6), 568-578 (2010-11-10)
The present study investigated the protective actions of des-aspartate-angiotensin I (DAA-I) in mice that were intranasally administered 2-chloroethyl ethyl sulfide (CEES), a half sulfur mustard. The protection was dose-dependent, and an oral dose of 75 mg kg⁻¹ per day administered
Qiang Wen et al.
European journal of pharmacology, 768, 173-181 (2015-11-03)
DAA-I (des-aspartate-angiotensin I), an endogenous angiotensin, had been shown earlier to ameliorate animal models of cardiovascular diseases via the angiotensin AT1 receptor and prostaglandins. The present study investigated further the action of DAA-I on the release of PGE2, PGI2, PGF2α
Meng-Kwoon Sim
European journal of pharmacology, 760, 36-41 (2015-04-22)
The review describes DAA-I (des-aspartate-angiotensin-I) as a prototype of a novel class of drugs that acts as agonists on the angiotensin AT1 receptor or ARAs (angiotensin receptor agonists). DAA-I is a component of the renin angiotensin system. Earlier studies showed
Yong-Chiat Wong et al.
Biochemical pharmacology, 82(9), 1198-1208 (2011-08-02)
Although clinical studies suggested that blockade of the renin-angiotensin system may prevent diabetes, the mechanism is uncertain. As a follow-up to an earlier study, we investigated how des-aspartate-angiotensin-1 (DAA-1) and its metabolite, angiotensin IV (Ang-IV) improved glucose tolerance in diet-induced
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持